Cardiovascular · Pulmonary Arterial HypertensionTrial Updateclinicalmid-term

Regeneron initiates study of REGN13335 for Pulmonary Arterial Hypertension

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Regeneron7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:31:52 AM

Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the REGN13335 trial by Regeneron is significant as it introduces a potential new treatment in a competitive market dominated by established therapies. Monitoring the trial's outcomes is crucial for understanding Regeneron's positioning and potential shifts in market dynamics. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 11 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should monitor REGN13335's trial outcomes as they could influence Regeneron's strategy in the PAH space and competitive positioning against existing therapies. The strongest clinical anchor is Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) (ClinicalTrials.gov), sub-indication match (cardiology); entity match (regeneron). In cardiology, 3 regulatory and 1 competitive items passed relevance filtering for Regeneron.

Competitive Pressure

The most relevant competitive pressure comes from Trial on Oxygen Saturation Targeting in Preterm Infants with Pulmonary Hypertension (Humanexa Signals) — sub-indication match (cardiology). This trial positions REGN13335 as a potential new treatment option in the PAH market, which is currently dominated by established therapies.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The trial's results will be critical for future regulatory submissions and could influence labeling and compliance requirements for REGN13335.

Key Risks

Elevated medium regulatory exposure for Regeneron could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Regeneron through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population) could weigh on Regeneron through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If successful, REGN13335 could capture market share from existing PAH therapies, impacting revenue streams for both Regeneron and competitors.
Upside for Regeneron may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Portfolio teams should monitor REGN13335's trial outcomes as they could influence Regeneron's strategy in the PAH space and competitive positioning against existing therapies.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results on safety and efficacy, as well as data on antibody formation against REGN13335.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology); Entity match (regeneron)
FDA document
View source
Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Pulmonary Hypertension (PH) Biorepository for Translational Research
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
An Effectiveness Trial of the PrEP for WINGS Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Trial on Oxygen Saturation Targeting in Preterm Infants with Pulmonary Hypertension
Humanexa Signalsmedium relevance
Sub-indication match (cardiology)
Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalslow relevance
Sponsor/company relevance (Merck)

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.
PubMedmedium relevance
Sub-indication match (cardiology)
FDA document
View source
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Regeneron
REGN13335

Commercial impact

medium

If successful, REGN13335 could capture market share from existing PAH therapies, impacting revenue streams for both Regeneron and competitors.

Regulatory impact

medium

The trial's results will be critical for future regulatory submissions and could influence labeling and compliance requirements for REGN13335.

What to watch

Key milestones include interim results on safety and efficacy, as well as data on antibody formation against REGN13335.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.